What is Relugolix CAS 737789-87-6?

Relugolix is a non-peptide, orally active gonadotropin-releasing hormone receptor antagonist supplied as a pharmaceutical API. Its molecular formula is C₂₉H₂₇F₂N₇O₅S and its molecular weight is about 623.63 g/mol.

What is Relugolix used for?

Relugolix is used in the manufacture of oral medicines for hormone-dependent conditions. Approved applications include advanced prostate cancer and symptomatic uterine fibroids, and it has been studied for endometriosis.

Are TAK-385 and RVT-601 the same as Relugolix?

Yes. TAK-385 and RVT-601 are developmental code names for relugolix, so they refer to the same GnRH receptor antagonist under CAS 737789-87-6. Altropane is a different compound and should not be used to identify this API.

How should Relugolix API be stored and handled?

Use qualified pharmaceutical handling procedures and protect the material from moisture, light and contamination. Supplier datasheets commonly recommend long-term powder storage at -20 °C; confirm the exact storage condition with the batch documentation.

Relugolix CAS 737789-87-6

Relugolix (CAS 737789-87-6) is a non-peptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist supplied as an Active Pharmaceutical Ingredient (API). Confirm the required grade, then request a quotation with COA/TDS/SDS for bulk supply.

CAS: 737789-87-6
Synonyms: TAK-385, RVT-601, Relugolix API
Molecular Formula: C₂₉H₂₇F₂N₇O₅S
Grade: Pharmaceutical Grade
Package: 25 kg/drum

Request a quote

Share:

Product Description

Relugolix, CAS 737789-87-6, is a non-peptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist supplied as an Active Pharmaceutical Ingredient (API).

Synonyms: TAK-385; RVT-601; Relugolix API.

CAS: 737789-87-6.

Molecular formula: C₂₉H₂₇F₂N₇O₅S.

Molecular weight: 623.63.

It is a white to off-white crystalline powder with a melting point of about 228 °C.

Supplier data report DMSO solubility around 20 mg/mL and ethanol solubility around 1.0 mg/mL; the predicted density is about 1.442 g/cm³.

It competitively blocks GnRH receptors in the pituitary gland, reducing luteinizing hormone, follicle-stimulating hormone and downstream sex hormone levels.

It is used as an API in oral formulations for advanced prostate cancer and symptomatic uterine fibroids.

It has been studied for endometriosis and other hormone-dependent indications.

Unlike peptide-based GnRH analogs, this small molecule allows oral dosing with a defined bioavailability profile.

Confirm identity, assay, related substances, residual solvents, water content, particle size and polymorphic form for the intended formulation.

Store protected from moisture and light; supplier datasheets commonly recommend long-term powder storage at -20 °C.

Handle under qualified pharmaceutical procedures with suitable PPE; follow the current SDS for spill, disposal and first aid.

Confirm the current product-specific specification.

Confirm packaging with the requested quantity and destination requirements.

Document requirements should be confirmed from the current specification, SDS, COA or other product-specific files.

The page is an RFQ entry point and does not state stock, price, MOQ or fixed lead time.

For an RFQ, state the intended use, required specification, quantity, packaging, destination and document needs.

FAQ - Technical & Supply Chain

Q:
What is Relugolix CAS 737789-87-6?

A: Relugolix is a non-peptide, orally active gonadotropin-releasing hormone receptor antagonist supplied as a pharmaceutical API. Its molecular formula is C₂₉H₂₇F₂N₇O₅S and its molecular weight is about 623.63 g/mol.
Q:
What is Relugolix used for?

A: Relugolix is used in the manufacture of oral medicines for hormone-dependent conditions. Approved applications include advanced prostate cancer and symptomatic uterine fibroids, and it has been studied for endometriosis.
Q:
Are TAK-385 and RVT-601 the same as Relugolix?

A: Yes. TAK-385 and RVT-601 are developmental code names for relugolix, so they refer to the same GnRH receptor antagonist under CAS 737789-87-6. Altropane is a different compound and should not be used to identify this API.
Q:
What are the key physical properties of Relugolix API?

A: It is a white to off-white crystalline powder with a melting point around 228 °C. Supplier data report DMSO solubility around 20 mg/mL and ethanol solubility around 1.0 mg/mL, with a predicted density of about 1.442 g/cm³.
Q:
How should Relugolix API be stored and handled?

A: Use qualified pharmaceutical handling procedures and protect the material from moisture, light and contamination. Supplier datasheets commonly recommend long-term powder storage at -20 °C; confirm the exact storage condition with the batch documentation.

Ordering & Documentation

Key information for document requests, quotations, and supply planning.

Documents

Tell us which documents your procurement team needs. Before an order, we will check whether the quoted source can provide them for the offered lot.

Quotation

Send the CAS number, grade, quantity, packing preference and destination.

Sample & Supply

Ask whether samples, trial quantities or repeat orders are possible. We will check each request against the sourced product and current offer.

Storage & Shipping

Product-specific conditions are confirmed before order.

Current Language

Change Language